Manufacturing Today Issue - 249 June 2026 | Page 224

________________________________________________________________________________________________________________________
through cell culture models, studying hair cells in vitro, which have demonstrated that less drug diffuses through the cell membrane, both actively and passively. In other words, through the use of the scalp cooling system, less of the drug is entering the cell and causing damage through the various mechanisms by which chemotherapy operates.
Committed to offering the best solution for cancer patients, Paxman recently joined forces with Dignitana, its main competitor, through an acquisition. It offered clear synergies and economies of scale, and while Dignitana had faced challenges, it brought with it an impressive customer base and team. Thus, merging the two businesses made complete sense. Paxman began exploring this opportunity at the end of 2024, before completing its due diligence in mid-2025 and making a formal offer in the second half of the year, which was accepted.
222